Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03440034 · ClinicalTrials.gov registry record · Phase 1
Study of Pioglitazone in Sporadic Inclusion Body Myositis
A Phase 1 study of Nervous System Diseases and Neuromuscular Diseases, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
- 1
- Study location
NCT03440034: Completed Phase 1 study of Nervous System Diseases and Neuromuscular Diseases, sponsored by Johns Hopkins University.
NCT03440034 is a Phase 1 study of Nervous System Diseases and Neuromuscular Diseases that has completed, run by Johns Hopkins University. The registered enrollment target is 19 participants, below the 323-participant average among 23 other Nervous System Diseases trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03440034, a Phase 1 study of Nervous System Diseases and Neuromuscular Diseases, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
A study looking at the effect of pioglitazone in skeletal muscle of patients with sporadic inclusion body myositis (sIBM).
Primary Outcome
Effect of 45 milligram pioglitazone dose on the expression of Peroxisome proliferator-activated receptor gamma coactivator 1-alpha target genes
Conditions Studied
Interventions
- DRUG Pioglitazone
Study Locations (1)
Maryland
- Johns Hopkins University - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2018-05-22 |
| Est. Completion | 2020-12-31 |
| Phase | Phase 1 |
What the finished NCT03440034 record still lists
NCT03440034 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 323-participant average among 23 other Nervous System Diseases trials with a reported enrollment target (94% lower).
The record links to 6 conditions, with Nervous System Diseases appearing as the primary indexed condition, and to 1 intervention - of which Pioglitazone is the first listed.
NCT03440034 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT03440034 about?
NCT03440034 is a clinical study titled "Study of Pioglitazone in Sporadic Inclusion Body Myositis". A study looking at the effect of pioglitazone in skeletal muscle of patients with sporadic inclusion body myositis (sIBM).
What is the current status of trial NCT03440034?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2018-05-22. Estimated completion is 2020-12-31.
What conditions does trial NCT03440034 study?
This clinical trial studies the following conditions: Nervous System Diseases, Neuromuscular Diseases, Inclusion Body Myositis, Myositis, Muscular Diseases.
What interventions are being tested in trial NCT03440034?
The interventions under investigation include: Pioglitazone (DRUG).
Who is sponsoring clinical trial NCT03440034?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03440034 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nervous System Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03440034's enrollment target sits among peer trials
19 21st of 23 higher than 3 of 23 other Nervous System Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Nervous System Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Deep Brain Stimulation Motor Ventral Thalamus (VOP/VIM) for Restoration of Speech and Upper-limb Function in People With Subcortical Stroke
RECRUITING · NA
-
SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
RECRUITING
-
The Effect of Transcutaneous Stimulation on Blood Pressure in Spinal Cord Injury (SCI)
RECRUITING · NA
-
Rett Syndrome Registry
RECRUITING
-
Sleep Healthy Using the Internet Mitigating Insomnia to Address Neurocognitive Difficulties (SHUTi MIND)
RECRUITING · Phase 2
-
Spinal Cord Transcutaneous Stimulation Effect on Blood Pressure in Acute Spinal Cord Injury (SCI)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI